Earnings Ahead

ARDS - Aridis Pharmaceuticals

0.7099 -0.0901 -11.26

Aridis Pharmaceuticals

Aridis Pharmaceuticals

About

Profile


Headquarters


Intraday

High
-
Low
-

52-week

High
-
Low
-

ARDS



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Aridis Pharmaceuticals GAAP EPS of -$0.44 beats by $0.07, revenue of $1.18M misses by $0.82M
  • Veru up 18% following late-breaking mid-stage data on sabizabulin for COVID-19
  • Aridis Pharmaceuticals GAAP EPS of -$0.92 misses by $0.59, revenue of $0.57M misses by $1.33M
  • Aridis stock rises 6% as antibody cocktail AR-701 protects against Omicron in animal models
  • MediciNova nabs new patent in Korea for MN-001 for treatment of blood cholesterol
  • Aridis wins funding from Gates Foundation to test inhalational COVID-19 antibodies
  • Aridis Pharma nearly doubles after its antibody cocktail retains effectiveness against Omicron variant
  • Aridis Pharmaceuticals EPS misses by $1.44, beats on revenue
  • Aridis Pharmaceuticals EPS beats by $0.14, misses on revenue
  • Freeline Therapeutics, Cytokinetics leads healthcare gainers; China SXT Pharmaceuticals, Atossa Therapeutics among major losers
  • Aridis inks suvratoxumab licensing agreement with AstraZeneca for up to $126M
  • Aridis falls ~20%, day after surging following COVID antibody cocktail data
  • Allied Healthcare Products, SCWorx leads healthcare gainers; Meridian Bioscience, Aridis Pharmaceuticals among major losers
  • Aridis surges 36% after COVID cocktail neutralizes delta variant in preclinical model
  • Bristol Myers wins positive CHMP opinion for Abecma in multiple myeloma
  • Aridis Pharmaceuticals EPS misses by $0.17
  • Aridis Pharmaceuticals EPS in-line
  • Aridis brokers agreement with Kermode for zoonotic viruses, shares surge 9%
  • Aridis Pharma's dual antibody cocktail could neutralize COVID-19 variants
  • Therapeutic Solutions stock rises after JadiCell deal
Date Price Open High Low Vol ER
May 10 0.990 1.100
1.100
0.990
110.14K
May 9 1.090 1.120
1.150
1.070
58.31K
May 6 1.140 1.160
1.190
1.130
89.43K
May 5 1.180 1.190
1.260
1.180
33.06K
May 4 1.210 1.180
1.230
1.180
41.92K
 
May 3 1.200 1.190
1.230
1.170
24.84K
May 2 1.230 1.210
1.250
1.184
22.89K
Apr 29 1.250 1.270
1.300
1.210
47.42K
Apr 28 1.260 1.280
1.300
1.200
20.79K
Apr 27 1.240 1.220
1.250
1.200
19.14K
Apr 26 1.220 1.250
1.251
1.180
71.54K
Apr 25 1.280 1.270
1.308
1.232
105.05K
Apr 22 1.320 1.320
1.410
1.260
90.03K
Apr 21 1.350 1.350
1.420
1.280
39.97K
Apr 20 1.370 1.480
1.480
1.360
33.91K
Apr 19 1.430 1.350
1.480
1.350
83.46K
Apr 18 1.280 1.430
1.430
1.275
59.73K
Apr 14 1.440 1.390
1.490
1.390
51.26K
Apr 13 1.410 1.470
1.470
1.381
24.17K
Apr 12 1.440 1.380
1.450
1.339
68.92K
Apr 11 1.430 1.490
1.490
1.340
34.51K